Fig. 2
Exploration of the potential biomarkers of drug sensitivity in ESCC. a A schematic diagram exploring potential biomarkers of drug sensitivity in esophageal squamous cell carcinoma. Eight ESCC patient-derived cells (PDCs) were established from an independent cohort of 123 ESCC patients. DNA sequencing was used to detect the mutations and gain/loss in ESCC PDCs. We used the ESCC PDCs for integrated targeted deep sequencing and drug sensitivity evaluation systems to explore potential biomarkers of drug sensitivity. b The mutational landscape was studied in eight ESCC PDCs. c Each circle represents a single drug–gene interaction, and the size is proportional to the number of mutant cell lines screened (range 1–7). An unpaired t test was performed for each drug–gene mutation associations. The top four drug–gene mutation associations sorted by FDR were colored by green (sensitive) and red (resistant)
